NASDAQ:MNLO - Menlo Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $11.37 -0.21 (-1.81 %) (As of 09/21/2018 04:00 PM ET)Previous Close$11.37Today's Range$11.19 - $11.8152-Week Range$6.99 - $39.86Volume806,562 shsAverage Volume228,734 shsMarket Capitalization$266.08 millionP/E Ratio-2.00Dividend YieldN/ABetaN/A Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryInsider TradesHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It is also developing products that are in Phase II clinical trials to treat pruritus associated with psoriasis, atopic dermatitis, and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California. Receive MNLO News and Ratings via Email Sign-up to receive the latest news and ratings for MNLO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:MNLO CUSIPN/A Webwww.menlotherapeutics.com Phone650-486-1416 Debt Debt-to-Equity RatioN/A Current Ratio18.07 Quick Ratio18.07 Price-To-Earnings Trailing P/E Ratio-2.00 Forward P/E Ratio-3.93 P/E GrowthN/A Sales & Book Value Annual Sales$4.58 million Price / Sales57.05 Cash FlowN/A Price / CashN/A Book Value($2.60) per share Price / Book-4.37 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees32 Outstanding Shares22,980,000Market Cap$266.08 million Menlo Therapeutics (NASDAQ:MNLO) Frequently Asked Questions What is Menlo Therapeutics' stock symbol? Menlo Therapeutics trades on the NASDAQ under the ticker symbol "MNLO." How were Menlo Therapeutics' earnings last quarter? Menlo Therapeutics Inc (NASDAQ:MNLO) posted its quarterly earnings results on Wednesday, August, 1st. The company reported ($0.36) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.75) by $0.39. The business had revenue of $10.14 million for the quarter, compared to the consensus estimate of $1.04 million. View Menlo Therapeutics' Earnings History. When is Menlo Therapeutics' next earnings date? Menlo Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for Menlo Therapeutics. What price target have analysts set for MNLO? 7 analysts have issued twelve-month price objectives for Menlo Therapeutics' shares. Their forecasts range from $11.00 to $48.00. On average, they anticipate Menlo Therapeutics' stock price to reach $33.00 in the next twelve months. This suggests a possible upside of 190.2% from the stock's current price. View Analyst Price Targets for Menlo Therapeutics. What is the consensus analysts' recommendation for Menlo Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Menlo Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Menlo Therapeutics. Who are some of Menlo Therapeutics' key competitors? Some companies that are related to Menlo Therapeutics include Rhythm Pharmaceuticals (RYTM), Vanda Pharmaceuticals (VNDA), CannTrust (CNTTF), Eagle Pharmaceuticals (EGRX), Dicerna Pharmaceuticals (DRNA), Geron (GERN), MacroGenics (MGNX), Rocket Pharmaceuticals (RCKT), Cara Therapeutics (CARA), Assembly Biosciences (ASMB), Aptinyx (APTX), Revance Therapeutics (RVNC), Amphastar Pharmaceuticals (AMPH), Amarin (AMRN) and Radius Health (RDUS). Who are Menlo Therapeutics' key executives? Menlo Therapeutics' management team includes the folowing people: Mr. Steven L. Basta, Pres, CEO & Director (Age 52)Ms. Kristine M. Ball CPA, Sr. VP of Corp. Strategy & CFO (Age 46)Dr. Paul S. Kwon M.D., Chief Scientific Officer (Age 47)Mr. Stuart D. Sedlack M.B.A., VP of Bus. Devel. (Age 53)Dr. Xiaoming Zhang Ph.D., Sr. VP of Non-Clinical & Pharmaceutical Devel. (Age 54) When did Menlo Therapeutics IPO? (MNLO) raised $86 million in an initial public offering on Thursday, January 25th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Piper Jaffray and Guggenheim Securities acted as the underwriters for the IPO and JMP Securities was co-manager. When did the company's lock-up period expire? Menlo Therapeutics' lock-up period expired on Tuesday, July 24th. Menlo Therapeutics had issued 7,000,000 shares in its IPO on January 25th. The total size of the offering was $119,000,000 based on an initial share price of $17.00. Since the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. Who are Menlo Therapeutics' major shareholders? Menlo Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (8.86%), Novo Holdings A S (6.25%), DAFNA Capital Management LLC (1.36%), Millennium Management LLC (0.93%) and First Manhattan Co. (0.13%). Company insiders that own Menlo Therapeutics stock include Presidio Partners 2007 Gp, LP and Vivo Capital Surplus Fund Viii. View Institutional Ownership Trends for Menlo Therapeutics. Which institutional investors are selling Menlo Therapeutics stock? MNLO stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC. View Insider Buying and Selling for Menlo Therapeutics. Which institutional investors are buying Menlo Therapeutics stock? MNLO stock was bought by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC, Millennium Management LLC, Novo Holdings A S and First Manhattan Co.. View Insider Buying and Selling for Menlo Therapeutics. How do I buy shares of Menlo Therapeutics? Shares of MNLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Menlo Therapeutics' stock price today? One share of MNLO stock can currently be purchased for approximately $11.37. How big of a company is Menlo Therapeutics? Menlo Therapeutics has a market capitalization of $266.08 million and generates $4.58 million in revenue each year. The company earns $-29,070,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Menlo Therapeutics employs 32 workers across the globe. What is Menlo Therapeutics' official website? The official website for Menlo Therapeutics is http://www.menlotherapeutics.com. How can I contact Menlo Therapeutics? Menlo Therapeutics' mailing address is 200 CARDINAL WAY 2ND FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-486-1416 or via email at [email protected] MarketBeat Community Rating for Menlo Therapeutics (NASDAQ MNLO)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 29 (Vote Outperform)Underperform Votes: 41 (Vote Underperform)Total Votes: 70MarketBeat's community ratings are surveys of what our community members think about Menlo Therapeutics and other stocks. Vote "Outperform" if you believe MNLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNLO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/22/2018 by MarketBeat.com StaffFeatured Article: Do You Need a Fiduciary?